UNSPSC 51101620: Iodoquinol

This classification denotes an antiprotozoal agent with the molecular formula C9H5I2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63W7IE88K8, chemically known as 5,7-diodo-8-quinolinol but generally known as diiodohydroxyquinoline, which bears US NIH Compound Identifier 3728. European Medicines Agency schedules Diiodohydroxyquinoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07142MIG. The term DIIODOHYDROXYQUINOLINE is an International Non-Proprietary Name.

World Health Organization schedules diiodohydroxyquinoline in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, IODOQUINOL remains the US FDA Preferred Term for this commodity. Iodoquinol bears US NLM identifiers UMLS ID C0012341 and NCI Concept Code C76008. SMILES: IC1C2C(NCCC2)C(O)C(I)C1.

UNSPSC 51101620 Iodoquinol is a Commodity code representing specific pharmaceutical products procured by state and local health agencies. Recent opportunities show state and local governments buying pharmaceutical supplies through piggyback contracts and direct competitive bidding processes, though the posted opportunities reveal minimal alignment with iodoquinol specifically — Illinois Department of Public Health procured antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) through a cooperative purchasing vehicle, and Seminole County, Florida solicited Naloxone and drug deactivation systems. The code itself identifies a narrow product line, and state and local purchasing under this Commodity appears to flow primarily through pharmaceutical warehousing agreements, cooperative consortia such as MMCAP Infuse, and county health department procurement. Issuing bodies include state health departments and county governments with public health missions. The scope of recent activity suggests that when this code is used, it reflects state and local procurement of specific pharmaceutical inventory for public health stockpiling, emergency preparedness, or clinical distribution rather than broad pharmaceutical sourcing.

Geographic activity in the most recent opportunities centers on Illinois and Florida, with the Illinois Department of Public Health executing a $2.99 million three-year contract through the MMCAP Infuse consortium awarded to Chartwell Rx LLC in August 2026, and Seminole County releasing a competitive IFB with a July 26, 2023 response deadline for annual pharmaceutical supplies. The Illinois procurement demonstrates the use of cooperative purchasing vehicles to manage pharmaceutical costs at scale, while Seminole County's approach shows county-level direct solicitation with quarterly delivery requirements and FEMA-potential funding streams. Activity under this Commodity code appears episodic and tied to specific public health supply needs rather than routine purchasing; the recent posted opportunities do not reflect active open bidding for iodoquinol itself, signaling either specialized demand or occasional procurement cycles.